A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Summary

This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, pharmacokinetics (PK), and antiviral activity (Part 3 only) of orally administered AL-611 in healthy volunteers (HV; Parts 1-2) and subjects with CHC (Part 3). Part 1: HV will receive 1 of 5 single ascending doses (SAD) of AL-611 Part 2: Eight HV from Cohort 3 in Part 1 are planned to receive a second single dose of AL-611 or placebo (as per their randomized assignment in Part 1) in a fed state after a washout period Part 3: Subjects with CHC infection will receive 1 of 3 planned multiple ascending doses (MAD)

Timeline

Start

2017-07-07

Primary completion

2017-09-18

Completion

2017-09-18

Outcome

Outcome not reported

Stopped (Business): “Strategic decision to discontinue further development of investigational compounds for the treatment of hepatitis C.”

Publications

• Corneillie L, Meziere L, Montpellier C, Drouet B, Aliouat-Denis CM, Cocquerel L. Update on the molecular and cellular biology of hepatitis E virus and therapeutic opportunities. Antiviral Res. 2026 Mar;247:106353. doi: 10.1016/j.antiviral.2026.106353. Epub 2026 Jan 20.

Drugs

Indications